The days of maintaining paper records across the life sciences development and production pipeline are gone. Today’s regulatory requirements, not to mention the complexity of new treatments, requires organization that can only be provided electronically. However,...
There can be little question that Industry 4.0 technologies are reshaping the way life sciences companies operate. In the wake of the rapid development of vaccines during the COVID-19 pandemic, more facilities than ever are being “born digital.” Some of these...
On Monday at the Emerson Exchange Users’ Conference, Emerson’s Michalle Adkins and AbbVie’s Jeff Ziolkowski moderated a panel with Fujifilm’s Soren Skerris, Takeda’s Dr. Nina Schwalb, Eli Lilly’s James Weber, and Emerson’s Christian Berg. The experts shared the...
While the idea of adding costs to a food and beverage or pharmaceutical industry process like Clean-in-Place/Steam-in-Place (CIP/SIP) has not traditionally been an easy decision, in today’s industrial environment that has changed. With the retirement of experts, the...
The life sciences marketplace is changing faster than nearly any other industry. Gone are the days when companies focus on a single treatment to drive their entire business. Today’s life sciences manufacturers are challenged to bring new treatments to the marketplace...
Christian Berg describes some solutions and technologies which facilitate the pursuit of the adaptive plant for manufacturers in the Life Sciences industry, as defined by the BioPhorum Digital Plant Maturity Model.
In a Pharma Focus Asia webinar, Pursuing the Adaptive Plant to Enable Personalized Healthcare, Emerson’s Christian Berg provides a broader perspective of personalized healthcare and its challenges for the Life Sciences industry.
Sean Buckley and co-authors from Roche, Takeda, and BioPhorum author CGT [cell & gene therapy] Actors and Process Maps which highlight six common types of CGT showing how the pattern of actors and process blocks varies by therapy type.
The BioPhorum Operations Group (BPOG) established a digital plant maturity model (DPMM) for biopharmaceutical manufacturing to define stages of factory evolution “from simple paper-based plants through to the fully automated and integrated ‘adaptive plant’ of the future.” The model gives organizations a common tool for industry comparison and measurement of progress. It also provides a platform to facilitate collaboration within the life sciences industry and its technology providers.
Traditional manufacturing practices have served the biopharmaceutical industry well for years, but times are changing and a need for speed to market in life sciences while reducing manufacturing costs is putting a focus on enabling real-time release (RTR)....
The BioPhorum CGT Personas and User Stories toolkit details the needs of all the key players involved in end-to-end cell and gene therapy (CGT) processes. It can be used by anyone who wishes to better understand how IT systems can support the manufacture and delivery of CGTs.
One of the key stages delaying and increasing costs in life sciences projects is equipment validation. In fact, it is one of the elements of project completion that project teams are most eager to compress because the value of every incremental improvement is so...
We invite you to follow us on Facebook, LinkedIn, Twitter and YouTube to keep up to date on all the latest news, events and innovations to help you take on and solve your toughest challenges.
Please do, Just link back to the post and send us a quick note so we can share your work. Thanks!
Our Global Community
The opinions expressed here are the personal opinions of the authors. Content published here is not read or approved by Emerson before it is posted and does not necessarily represent the views and opinions of Emerson.